HIV-1 entry into host cells is mediated by the sequential binding of the envelope glycoprotein gp120 to CD4 and a chemokine receptor. Antibodies binding to epitopes overlapping the CD4-binding site on gp120 are potent inhibitors of HIV entry, such as the llama heavy chain antibody fragment VHH D7, which has cross-clade neutralizing properties and competes with CD4 and mAb b12 for high affinity binding to gp120. We report the crystal structure of the D7 VHH at 1.5 Å resolution, which reveals the molecular details of the complementarity determining regions (CDR) and substantial flexibility of CDR3 that could facilitate an induced fit interaction with gp120. Structural comparison of CDRs from other CD4 binding site antibodies suggests diverse modes of interaction. Mutational analysis identified CDR3 as a key component of gp120 interaction as determined by surface plasmon resonance. A decrease in affinity is directly coupled to the neutralization efficiency since mutations that decrease gp120 interaction increase the IC50 required for HIV-1 IIIB neutralization. Thus the structural study identifies the long CDR3 of D7 as the key determinant of interaction and HIV-1 neutralization. Furthermore, our data confirm that the structural plasticity of gp120 can accommodate multiple modes of antibody binding within the CD4 binding site.
Citation: Hinz A, Lutje Hulsik D, Forsman A, Koh WW-L, Belrhali H, Gorlani A, et al. (2010) Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction. PLoS ONE 5(5): e10482. doi:10.1371/journal.pone.0010482
Editor: Jean-Pierre Vartanian, Institut Pasteur, France
Received: January 29, 2010; Accepted: April 14, 2010; Published: May 5, 2010
Copyright: © 2010 Hinz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was conducted as part of the Collaboration for AIDS Vaccine Discovery with support from the Bill and Melinda Gates Foundation (to W. W., R. A. W. and T. V.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
The envelope glycoprotein (Env) from the human immunodeficiency virus type 1 (HIV-1) forms a heterotrimer composed of the receptor binding subunit gp120 and the membrane anchored fusion protein subunit gp41. Entry into host cells is mediated by gp120 interaction with CD4 that triggers a conformational change allowing subsequent interaction with cellular coreceptors such as CCR5 or CXCR4 –. Together these events trigger a refolding of gp41 that leads to the fusion of virus and host cell membranes –. Env is the target for entry inhibitors  and neutralizing antibodies directed against gp120 and gp41 . A main problem in HIV-1 vaccine research is the generation of cross-subtype neutralizing antibodies, which is due to the fact that HIV-1 employs a number of strategies to evade the immune response. This includes highly variable gp120 regions, a carbohydrate shield  and conformational masking of the receptor binding site . The overall conformational flexibility of gp120 is highlighted by the differences between the native SIV gp120 core structure  and structures representing the CD4- and antibody-induced conformations of the HIV-1 gp120 –. Gp120 structures are composed of an inner and an outer domain; the inner domain varies substantially including the refolding of the bridging sheet, while the outer domain harbouring the CD4 binding site is mostly conserved except for the refolding of the CD4-binding loop , . The conformational flexibility is considered to be the main obstacle to the development of an HIV-1 vaccine, besides the sequence variability and the glycan shield. Consequently, only few broadly neutralizing antibodies have been described to date . MAbs 2F5, 4E10 and Z13 recognize epitopes within the membrane proximal region of gp41 –, mAb 2G12 recognizes a carbohydrate motif , , b12 interacts within the CD4 binding site , , HJ16 overlaps with the CD4 binding site  and antibodies PG9 and PG16 are specific for the trimeric Env conformation .
The crystal structure of gp120 in complex with b12 revealed the molecular details including a substantial conserved gp120 surface overlapping between both the CD4- and b12-bound states . The similarities of both interactions is highlighted by the fact that b12 employs Tyr53 to fill the hydrophobic pocket in gp120 that is otherwise occupied by CD4 Phe43 . MAb b12 is broadly neutralizing since it engages gp120 at the same exposed surface in a similar manner as CD4, albeit it does not require the induction of further conformational changes . The CD4 binding site is highly conserved, but nonetheless not all antibodies targeting the CD4 binding site show broad cross-clade neutralization properties including F105, M12 and M14 for example , –. No breakthrough has yet been reported regarding the efficient generation of broadly neutralizing monoclonal antibodies upon immunization of animals with Env antigens ,  except for the generation of camelid antibodies. Three heavy chain only camelid specific antibody domains D7, A12 and C8, termed VHH, have been isolated after immunization with gp120. These antibodies compete with CD4 and b12 for gp120 interaction and exert neutralizing activity against primary isolates of subtypes B and C .
Here we describe the crystal structure of the camelid VHH D7 and determine the molecular determinants for HIV-1 Env gp120 interaction. Mutagenesis of selected CDR residues abrogate or enhance gp120 interaction in vitro and correlate with the neutralization activity of D7 against the B-clade HIV-1 IIIB thus providing a molecular model for D7-gp120 reactivity.
Results and Discussion
Structure of the VHH D7
The crystal structure of the llama heavy chain antibody fragment VHH D7 was solved by molecular replacement and refined to a resolution of 1.5 Å with an R factor of 16.6% and an Rfree of 19.4% (table 1). D7 folds into a typical immunoglobulin domain closely resembling known llama VHH structures  (Figure 1A). It contains two canonical (CDR1 and CDR2) and a long CDR3 typical for llama VHHs  with a non-canonical CDR conformation . CDR3 is composed of 18 residues (Lys95 – Tyr102) (Figure 2). The base of CDR3 is well defined and stabilized by multiple main chain and side chain interactions including hydrogen bonds and salt bridges with CDR1 (Ser31-Arg97, Asp33-Lys95, Asp33-Arg97 and Asp33-Ser100F) and CDR2 (Ser52-Asp100C and Thr56-Asp100C) (Figure 1B). The extensive inter CDR stabilization suggests a potentially lower flexibility of the CDRs upon binding to gp120. The CD4 binding site antibody b12 employs only one polar (Ser30-Tyr53) and few hydrophobic inter heavy chain CDR contacts , . However, the tip of the D7 CDR3 (Arg100 - Ser100B) is highly mobile evidenced by the lack of continuous main chain density for three residues, including Tyr100A positioned at the apex of CDR3, indicating that their conformational flexibility might be important for gp120 recognition.
(A) Ribbon representation of D7; the complementarity determining regions (CDR) are highlighted in yellow (CDR1), orange (CDR2) and salmon (CDR3). The first and last residue of each CDR is shown together with the side chain of Trp96 critical for gp120 interaction and neutralization. The dotted line indicates CDR3 residues lacking continuous main chain density for residues Arg100 to Ser100B. (B) A close-up of the CDR interaction network reveals multiple polar interactions between CDR1 and CDR3 as well as CDR2 and CDR3.
The residue numbering is according to Chothia  and the CDRs are indicated by coloured bars.
Structural comparison of CD4 binding site antibodies
D7 was shown to interfere with CD4 and b12 binding on gp120 and exerts a decent neutralization profile of primary HIV-1 clade B and C isolates . Its neutralization capacity is similar to that of b12, although b12 is more potent and both antibodies neutralize a different spectrum of viruses . MAb b12 employs only the heavy chain to interact with gp120, indicating that a heavy chain only antibody such as the D7 VHH could mimic its interaction with gp120. All three b12 heavy chain CDRs contact gp120, notably mostly its outer domain . The overlap between the b12 and the CD4 buried surfaces are considerable and both modes of interaction employ aromatic residues to fill a hydrophobic pocket on gp120 (b12 Tyr53 of CDR2 and CD4 Phe43) , . Three other crystal structures of CD4 binding site mAbs are known, namely those of unliganded F105 and m18 Fabs ,  and F105 and b13 in complex with gp120 . F105, b13 and m18 interfere with CD4 binding on gp120, neutralize several HIV-1 strains but exert lower potency in neutralization of primary isolates as compared to b12 , , –. The structures of gp120 in complex with F105 and b13 show that it does not suffice to occupy the CD4 binding site in order to exert broad neutralizing activity since the orientation of gp120 recognition is most likely not compatible with binding to the trimeric Env present on virions .
CD4 binding site antibodies b12, b13, F105 and m18 display a similar architecture of their CDR3 heavy chains with aromatic residues positioned at the apex of their CDR3 (Figure 3A). This feature led originally to the proposal that this class of antibodies employs aromatic CDR residues to fill the gp120 pocket that is occupied by Phe43 in the CD4- bound state , . Although b12 and b13 point their CDR2 residue Tyr53 and Tyr52A, respectively, towards the CD4 binding pocket , mAb F105 employs CDR3 Phe100A and Tyr100B within the CD4 binding site .
The Cα atoms of the heavy chain variable domains (b12 pdb code 2NY7; F105 pdb code 3HI1; b13 pdb code 3IDX; m18 pdb code 2AJ3) were superimposed and the CDR H2 and H3 are represented in the same orientation. Amino acids are labelled using the one letter code for clarity. (A) All CDR3 loops expose aromatic residues at their apex. (B) The CDR2 of D7 varies from CDR H2 of b12 indicating a different mode of gp120 interaction. Residues implicated in gp120 interaction are highlighted in orange.
Sequence alignment of D7 with the heavy chain sequences of b12, b13, F105 and m18 reveals aromatic residues within CDR2 and CDR3 (Figure 2). Comparison of the CDR2 loops shows Tyr53 at the apex of F105 CDR2, no aromatic residue at the apex of m18 CDR2 and Tyr53 and Tyr52a at the apex of b12 and b13 CDR2. The CDR2 of D7 contains Trp52A, which is however not solvent accessible. Instead D7 Trp52A is involved in CDR1 stabilization as observed in another VHH structure  (Figure 3B). It is thus unlikely that D7 CDR2 plays a prominent role in gp120 interaction as observed for CDR2 from b12 and b13.
We thus focused our analysis on the CDR3 region as a potential gp120 interaction site. Part of this loop region is highly mobile in the absence of ligand and thus suitable for an induced fit conformation. CDR3 of D7 is tilted 40° towards CDR2 compared to the orientation of the CDR H2/H3 of the other antibodies, whereas the apex of CDR3 is also built by an aromatic residue (Tyr100A) like in b12 (Trp100), F105 (Phe100A and Tyr100B), b13 (Tyr100C) and m18 (Phe99). Notably, b12 employs a number of CDR H3 residues to contact gp120 including Trp100 (Figure 3B). However, despite the fact of aromatic residues at the tip of all CDR3 loops, no significant structural homology between the CDR loops can be observed underlining the differences in mode of gp120 interaction.
Mutational analysis of D7 binding to gp120
We performed mutational analysis within CDR3 to substantiate the role of CDR3 in gp120 interaction by determining the affinity of the D7 mutants in comparison to the wild type using surface plasmon resonance. Mutagenesis of solvent exposed CDR3 residues Lys95Ser, Trp96Ala and Leu99Ala (Figures 2 and 3A; table 2) decreased the affinity of D7 to gp120 (IIIB) significantly to 377, 27 and 69 nM, respectively, compared to 2.9 nM of wild type D7 (table 3). Note that the affinity of D7 to gp120 determined here is ∼30 times lower than the previously reported KD of 0.097 nM . In contrast, mutagenesis of solvent exposed residues Asp100C, Asn100D and the double mutant Asn101Tyr Tyr102Asp (table 2) enhanced the affinity to 0.84, 0.51 and 0.18 nM (table 3). Notably, the double mutation at position 101 and 102 to Tyr and Asp restores the CDR3 sequence of VHH A12 (Figure 2), which has broader neutralization potency than D7 . Mutagenesis of Tyr100A located at the tip of CDR3 (Figure 3A) has no significant effect on binding (table 3). The moderate increase of affinity by mutagenesis of Asp100C and Asn100D might reflect a decrease of the rigidity of the loop since loop stabilizing interactions are affected (table 3 and Figure 1B). This could lead to an improved induced fit upon gp120 binding facilitated by an increased CDR flexibility. The positive effect of the double mutation of Asn101Tyr102 on interaction together with their close location next to Trp96 and Lys95 suggest that they affect binding directly. Finally, the strong decrease in affinity upon mutagenesis of residues Lys95, Trp96 and Leu99 indicate that these residues make crucial contributions to gp120 interaction. The decrease in affinity is mainly due to an increase of the dissociation rate of the D7 mutants (table 3), which suggests a change of interaction between the CDR3 loop and gp120 but no major change of loop conformation. Together, these data implicate that VHH D7 interacts via CDR3 with gp120 and identify Lys95, Trp96 and Leu99 as key residues for this interaction. Both Lys95 and Trp96 at the beginning of CDR3 are solvent exposed while Leu99 is part of the disordered tip of CDR3, which adds to the conformational freedom of D7 interaction with gp120 (Figure 3A). All three residues are conserved in VHH A12 suggesting that it will utilize its CDR3 to contact gp120 in a similar way (Figure 2). A12 differs only at positions 100D (Tyr instead of Asn) as well as 101 and 102 (Asn, Tyr instead of Tyr, Asp). Further sequence differences that may account for the higher neutralization potency of A12 include CDR1 residues (Thr28 is changed to Ile28 and His32 to Tyr32 in A12) and CDR2 residue Asn58 (Asp58 in A12).
In order to confirm the role of CDR3 and the correlation of gp120 interaction and neutralization, wild type D7 and mutants were tested in a TZM-b1 neutralization assay against HIV-1 IIIB. Comparison of the IC50 values reinforces the importance of CDR3. Mutations that lead to decreased gp120 interaction, namely Ala mutations of Lys95 and Trp96, showed a 100-fold increase in IC50, and Leu99 revealed a 10-fold increase in IC50 as compared to D7 wild type (table 4). In contrast, mutation of Tyr100A and Asp100C show a modest decrease in the IC50 (table 4) consistent with a slightly increased affinity for gp120 (table 3). The largest positive effect was observed for the double mutant Asn101Tyr102, which shows a ∼10-fold increase in affinity (table 3) and a reduction of the IC50 value by a factor of 5 (table 4). This underlines the important role of CDR3 (Figure 4A) for neutralization of HIV-1. Since the CD4 binding site on gp120 is negatively charged  CDR3 could provide some complementary basic charge for interaction (Figure 4B). Together these findings indicate that the differences related to CDR3 constitute an important factor accounting for the broader neutralization profile of A12 compared to D7  since both CDR1 and CDR2 are almost identical (Figure 2). It is thus possible that C8 employs different structural principles for gp120 interaction and neutralization .
(A) Surface representation of D7 revealing the gp120 docking interface based on gp120 binding and HIV-1 neutralization results. The CDRs are coloured as in figure 1. CDR3 residues affecting gp120 interaction and HIV-1 IIIB neutralization are indicated in white and residue differences between D7 and A12 are labelled in black. (B) Electrostatic potential map of the surface generated by the CDRs.
The conformation of the primary receptor binding site of HIV-1 gp120 reveals a hydrophobic pocket which is the target for Phe43 of the natural receptor CD4  and overlaps with the binding sites of neutralizing antibodies b12 , b13 and F105 . The structural and mutational data presented here show that D7 does not expose an aromatic residue at its CDR2 and that Tyr100A at the apex of CDR3 does not play a key role in gp120 interaction and HIV-1 IIIB neutralization. Thus D7 might employ different structural principles than b12 to interact with gp120. This is further supported by preliminary results on the D7 interaction with HIV-1 envelope proteins gp140CN54, gp140UG37, gp120IIIB, gp120YU2 and its modified variant gp120Ds2, in which an additional S-S (109-428) bridge was introduced, thus closing the cavity below the bridging sheet . VHH D7 binds to gp120IIIB, gp140UG37 and gp120YU2 but is unable to interact with gp120Ds2 strongly indicating that D7 does not bind to the outer domain, as b12 does (A. Szynol personal communication). This is further supported by antibody recognition of a gp120 escape mutant. Whereas gp120 mutation G366E results in impaired binding of sCD4 and b12, the binding of D7 was not effected (A. McKnight, personal communication), further corroborating differences in gp120 interaction of b12 and D7. Although we identified Trp96 as a key residue for gp120 interaction and neutralization its position and limited extension form the core structure albeit its solvent exposure (table 4) does not conclusively indicate how it could reach into the hydrophobic CD4 binding pocket on gp120. Thus CD4 binding site antibodies might be broadly neutralizing without closely mimicking important molecular details of the CD4-gp120 interaction. Although the structure establishes a firm role for CDR3 and its flexible anchoring in interaction and neutralization activity, structural analysis of gp120 in complex with D7 is required to fully understand the conformational flexibility of both gp120 and D7 in order to exploit this knowledge for a rational vaccine design.
Materials and Methods
D7 purification, crystallization and structure solution
S. cerevisiae strain VWk18gal1 (CEN-PK102-3A, MATa, leu2-3, ura3, gal1::URA3, MAL-8, MAL3, SUC3) was used for the fermentative production of D7. The VHH D7 gene contains the following amino acid substitutions compared to wild type D7  in framework residues Val5Gln, Ala11Val, Ala61Val, Ala68Asp and Ser79Tyr, which occur naturally in other known VHH structures . The gene was integrated into the S. cerevisiae genome in the rDNA locus  and grown as described . VHH D7 was purified from the supernatant using Ni2+-affinity chromatography in PBS. A final size exclusion chromatography was performed on a Superdex 200 (GE Healthcare) in a buffer containing 20 mM HEPES pH 7, 0.1 M NaCl. VHH D7 was crystallized using the hanging drop vapor diffusion method at room temperature. Crystals formed by mixing D7 (at 5 mg/ml) with an equal volume of 100 mM sodium cacodylate pH 6, 20 mM magnesium acetate, 1.7 M ammonium sulphate and 19% glycerol. Crystals were flash frozen in liquid nitrogen using 30% glycerol as cryo-protectant. A native dataset was collected to a resolution of 1.5 Å at ESRF beam line (Grenoble, France) BM14. The dataset was processed with MOSFLM  and SCALA , . The crystals belong to space group P212121 with unit cell dimensions of a = 37.37 Å, b = 62.18 Å, c = 62.74 Å containing 1 molecule in the asymmetric unit.
The structure was solved by molecular replacement using the program PHASER  and the VHH structure pdb code 1HCV as a search model. The initial model was built using ARPWARP  and completed by several cycles of manual rebuilding in COOT  and refinement in REFMAC  and PHENIX  to Rwork/Rfree values of 0.1657/0.1935. The final model contains 127 residues, 189 water molecules and 4 sulfates (see table 1). All molecular graphics figures were generated with PYMOL (W Delano; http://www.pymol.org/). Coordinates and structure factors of D7 have been deposited in the Protein Data Bank with accession number 2xa3.
Mutation of VHH D7 and Surface Plasmon Resonance analysis of D7 binding to gp120
Mutations of the VHH D7 sequence  were generated by using the quick change mutagenesis kit (Stratagene). The mutations were verified by sequencing. Wild type and mutant VHH D7 proteins were expressed in E. coli and purified following the protocol for wild type D7 purification .
Gp120 (IIIB) was coupled covalently to channel 2 of a CM5 chip (GE Healthcare) following the manufacturer's instructions. Briefly, the CM5 chip was activated with 50 µL EDC/NHS at a flow rate of 25 µl/min. Adsorption of 100 µl gp120 was carried out in a buffer containing 25 mM sodium acetate pH 5. Deactivation of the surface was achieved with 50 µl diethanolamine. Chanel 1 was treated similar but skipping the step of gp120 adsorption. All binding experiments were performed on a Biacore X (GE Healthcare) in a buffer containing 10 mM HEPES pH 7.5, 100 mM NaCl, 0.05% P20 at a flow rate of 30 µl/min. The association of 90 µl D7 or D7 mutants at concentrations of 25 and 100 nM was recorded for 3 min followed by a dissociation of 15 min. The CM5 chip was regenerated with a 20 µl pulse of 0.1 M glycine pH 2 at a flow rate of 50 µl. Data were evaluated with the BiaEvaluation software (GE Healthcare) using simultaneous fit of association and dissociation.
HIV-1 neutralization in TZM-bl cells
HIV-1 neutralization in TZM-bl cells was evaluated using an assay developed previously , , . Three-fold serial dilutions of VHH (starting at 20 µg/ml) were prepared in growth medium (DMEM containing 10% FCS) in duplicate wells of opaque 96-well cell culture plates, in a total volume of 50 µl per well. Approximately 200 TCID50 of virus, in 50 µl of growth medium, was added to each well, and the plates were subsequently incubated at 37°C. After 1 hour of incubation, 1 ⋅ 104 newly trypsinized TZM-bl cells in 100 µl of growth medium containing 30 µg/ml of DEAE-dextran (Sigma-Aldrich) were added to each well. For each plate, six wells containing cells and growth medium only, and six wells containing virus and cells only, were included. The neutralization activity of each VHH was assayed in duplicate. The plates were then incubated at 37°C for 48 hours and detection of infection of TZM-bl cells was assayed by measuring luminescence production according to the manufacturer's instructions (Promega). Lysis of cells was allowed to occur for 2 minutes and luminescence (in relative light units; RLU) was then detected using a GloMax 96 Luminometer (Promega). Neutralization was measured as the reduction in RLU in test wells compared to virus control wells after subtraction of background luminescence. The lowest VHH or antibody concentration required to give 50% reduction in RLU (IC50) was determined by fitting the data to a sigmoidal equation using the XLFit 4 software (IDBS).
We thank the Partnership for Structural Biology (PSB; http://www.psb-grenoble.eu) for access to the common platforms and the ESRF (Grenoble) staff for access to the beam lines.
Conceived and designed the experiments: RAW TCV WW. Performed the experiments: AH DLH AF WWLK. Analyzed the data: HB WW. Contributed reagents/materials/analysis tools: AG HdH. Wrote the paper: RAW TCV WW.
- 1. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, et al. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763–767.
- 2. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, et al. (1984) T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312: 767–768.
- 3. Moore JP, Trkola A, Dragic T (1997) Co-receptors for HIV-1 entry. Curr Opin Immunol 9: 551–562.
- 4. Clapham PR, McKnight A (2002) Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol 83: 1809–1829.
- 5. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426–430.
- 6. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263–273.
- 7. Weissenhorn W, Hinz A, Gaudin Y (2007) Virus membrane fusion. FEBS Lett 581: 2150–2155.
- 8. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, et al. (2004) Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3: 215–225.
- 9. Sattentau Q (2008) Correlates of antibody-mediated protection against HIV infection. Curr Opin HIV AIDS 3: 368–374.
- 10. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705–711.
- 11. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678–682.
- 12. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, et al. (2005) Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433: 834–841.
- 13. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648–659.
- 14. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732–737.
- 15. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, et al. (2009) Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326: 1123–1127.
- 16. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, et al. (2009) Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A.
- 17. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232–13252.
- 18. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67: 6642–6647.
- 19. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17: 1757–1765.
- 20. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892–10905.
- 21. Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, et al. (2007) An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 81: 4033–4043.
- 22. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100–1108.
- 23. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol 76: 7306–7321.
- 24. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024–1027.
- 25. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, et al. (1994) Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 68: 4821–4828.
- 26. Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F, et al. (2010) Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals. PLoS ONE 5(1): e8805.
- 27. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–289.
- 28. Bagley J, Dillon PJ, Rosen C, Robinson J, Sodroski J, et al. (1994) Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120. Mol Immunol 31: 1149–1160.
- 29. Moore JP, McCutchan FE, Poon SW, Mascola J, Liu J, et al. (1994) Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 68: 8350–8364.
- 30. Thali M, Furman C, Ho DD, Robinson J, Tilley S, et al. (1992) Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 66: 5635–5641.
- 31. Posner MR, Cavacini LA, Emes CL, Power J, Byrn R (1993) Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr 6: 7–14.
- 32. Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, et al. (2004) Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol 78: 9233–9242.
- 33. Zhang PF, Cham F, Dong M, Choudhary A, Bouma P, et al. (2007) Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A 104: 10193–10198.
- 34. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143–155.
- 35. Forsman A, Beirnaert E, Aasa-Chapman MMI, Hoorelbeke B, Hijazi K, et al. (2008) Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120. J Virol 82: 12069–12081.
- 36. Spinelli S, Frenken L, Bourgeois D, de Ron L, Bos W, et al. (1996) The crystal structure of a llama heavy chain variable domain. Nat Struct Biol 3: 752–757.
- 37. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. (1993) Naturally occurring antibodies devoid of light chains. Nature 363: 446–448.
- 38. Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, et al. (1992) Structural repertoire of the human VH segments. J Mol Biol 227: 799–817.
- 39. Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, et al. (2004) The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 78: 3155–3161.
- 40. Wilkinson RA, Piscitelli C, Teintze M, Cavacini LA, Posner MR, et al. (2005) Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J Virol 79: 13060–13069.
- 41. Prabakaran P, Gan J, Wu YQ, Zhang MY, Dimitrov DS, et al. (2006) Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs. J Mol Biol 357: 82–99.
- 42. Litwin V, Nagashima KA, Ryder AM, Chang CH, Carver JM, et al. (1996) Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer. J Virol 70: 6437–6441.
- 43. D'Souza MP, Livnat D, Bradac JA, Bridges SH (1997) Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. J Infect Dis 175: 1056–1062.
- 44. Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, et al. (2003) Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 283: 17–25.
- 45. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, et al. (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293: 1155–1159.
- 46. Lopes TS, de Wijs IJ, Steenhauer SI, Verbakel J, Planta RJ (1995) Factors affecting the mitotic stability of high-copy-number integration into the ribosomal DNA of Saccharomyces Cerevisiae. Yeast 12: 467–477.
- 47. van de Laar T, Visser C, Holster M, Lopez CG, Kreuning D, et al. (2007) Increased heterologous protein production by Saccharomyces cerevisiae growing on ethanol as sole carbon source. Biotechnol Bioeng 96: 483–494.
- 48. Leslie AGW (1992) Recent changes to the MOSFLM package for processing film and image plate data. Jnt CCP4/ESF-EACMB Newslett Protein Crystallogr 26:
- 49. Evans P (2006) Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62: 72–82.
- 50. CCP4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 157–163.
- 51. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658–674.
- 52. Perrakis A, Morris R, Lamzin VS (1999) Automated protein model building combined with iterative structure refinement. Nat Struct Biol 6: 458–463.
- 53. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
- 54. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240–255 |.
- 55. Adams PD, Grosse-Kunstleve RW, Hung L-W, Loerger TR, McCoy AJ, et al. (2002) PHENIX: building new software for automated crystallographic structure determination. Acta Cryst D58: 1948–1954.
- 56. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, et al. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358–8367.
- 57. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896–1905.
- 58. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108–10125.